- Home
- AKA vs ZURA Comparison
AKA vs ZURA Comparison
Compare AKA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- ZURA
- Stock Information
- Founded
- AKA 2018
- ZURA 2022
- Country
- AKA United States
- ZURA United States
- Employees
- AKA N/A
- ZURA N/A
- Industry
- AKA Catalog/Specialty Distribution
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKA Consumer Discretionary
- ZURA Health Care
- Exchange
- AKA Nasdaq
- ZURA Nasdaq
- Market Cap
- AKA 251.5M
- ZURA 292.1M
- IPO Year
- AKA 2021
- ZURA N/A
- Fundamental
- Price
- AKA $17.85
- ZURA $3.16
- Analyst Decision
- AKA Buy
- ZURA Buy
- Analyst Count
- AKA 3
- ZURA 6
- Target Price
- AKA $25.00
- ZURA $15.80
- AVG Volume (30 Days)
- AKA 8.4K
- ZURA 342.4K
- Earning Date
- AKA 11-07-2024
- ZURA 11-07-2024
- Dividend Yield
- AKA N/A
- ZURA N/A
- EPS Growth
- AKA N/A
- ZURA N/A
- EPS
- AKA N/A
- ZURA N/A
- Revenue
- AKA $564,586,000.00
- ZURA N/A
- Revenue This Year
- AKA $4.56
- ZURA N/A
- Revenue Next Year
- AKA $3.92
- ZURA N/A
- P/E Ratio
- AKA N/A
- ZURA N/A
- Revenue Growth
- AKA 3.31
- ZURA N/A
- 52 Week Low
- AKA $6.74
- ZURA $2.00
- 52 Week High
- AKA $33.73
- ZURA $6.35
- Technical
- Relative Strength Index (RSI)
- AKA 30.40
- ZURA 29.68
- Support Level
- AKA $19.03
- ZURA $4.00
- Resistance Level
- AKA $26.52
- ZURA $4.85
- Average True Range (ATR)
- AKA 1.92
- ZURA 0.35
- MACD
- AKA -0.74
- ZURA -0.14
- Stochastic Oscillator
- AKA 16.30
- ZURA 0.59
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.